Biography
Interests
Ola Gaber1, Ihab Eldessouki1, Mohamed Magdy1, Mohamed Rahouma2*, Mohamed Kamel2, Massimo Baudo3, Abdelrahman Mohamed Abdelrahman2, Nagla Abdel Karim4 & John C. Morris1
1Vontz Center for Molecular Studies, Hematology-Oncology Department, University of Cincinnati, Ohio, USA
2Surgical Oncology Department, National Cancer Institute, Cairo University, Egypt
3Department of Cardiac Surgery, Spedali Civili di Brescia, Brescia, Italy
4Hematology-Oncology Department, Augusta University, GA, USA
*Correspondence to: Dr. Mohamed Rahouma, Surgical Oncology Department, National Cancer Institute, Cairo University, Egypt.
Copyright © 2018 Mohamed Rahouma, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Liquid biopsy including circulating tumor cells (CTC), circulating tumor DNA (ct DNA) and exosomes and has been an attractive concept to both researchers and clinicians due to its convenience, dynamicity, universality, and cost-effectiveness. However, when it comes to real life application, it was faced by so many challenges that delayed taking this practice to a more widespread scale and involving it in cancer guidelines. Perhaps one of the most important points made was that the controversial origin of different types of these biopsies and its effect on specificity. That point was greatly overcome by advancements in genetic material isolation and the sequencing techniques. Next-generation sequencing (NGS), a technology used to sequence DNA templates [1], has greatly helped overcome that point. Another crucial point was the representation of the cell dynamic that this biopsy conveys to us; does it represent necrosis, apoptosis, normal secretory mechanism that is part of the basic biologic functions, or a mixture of all that varies with the different cellular inputs. Virtosomes are DNA-RNA-lipoprotein complexes, which are synthesized exclusively by living cells. They have released in an energy-dependent, highly regulated manner within few hours of their formation. These unique characteristics that distinguish them from other forms make it a possibly highly specific and sensitive future biomarker.
What is a Liquid Biopsy?
Histopathological analysis of tumor tissues and cells is a cornerstone in the diagnosis of malignant conditions.
This practice has been done unchanged for past decades except for the introduction of improved quality to
treat and interpret the samples. The National Cancer Institute definition of a biopsy is the removal of cells
or tissues to be examined by a pathologist [2]. Recently, the introduction of liquid biopsy concepts gave a
novel perspective to this definition.
Liquid biopsies are samples obtained from non-solid biological tissue, mainly the blood, and derived from the primary tissue of interest [2]. The literature describes three main categories: circulating tumor DNA (ctDNA), circulating tumor cells (CTC) and exosomes.
The reason why DNA, cells, and exosomes are shed from tumors and healthy tissues are not fully known yet [3,4]; intercellular communication has been offered as a major cause, but other factors such as apoptosis, necrosis, and disposal of excess compounds were suggested as well. While considering liquid biopsies as cellular messengers confer depth to their role in disease development and body hemostasis, other theories lean towards assuming that they are the byproduct for more important process [5-9].
ctDNA is the free DNA released by tumor cells and detected in the blood, hence the name circulating. While most research is conducted on blood samples, researchers were able to isolate ctDNA from other body fluids such as urine and cerebrospinal fluid [8]. Physiologically, free DNA is released from the cells of healthy individuals and can be detected in their blood [4], but the levels of free DNA detected in diseased individuals are higher[10, 11].
As all liquid biopsies, the mechanism of DNA release from the cells is still controversial. One theory attributed DNA release to be a byproduct of necrosis as a result of increased cell turnover which over saturates the phagocytic capacity to remove debris [12]. This theory was supported by the length range of the DNA strands detected in the blood. Free DNA fragments length were also the reason why some researchers think apoptosis can be their primary source since recent reports mentioned fragment length range of 180- 200 bp that displayed the ladder pattern indicative of an apoptotic activity [9,13]. This can explain the surge in ctDNA levels in plasma after treatment administration. Another theory suggested that ctDNA is released from other circulating components in the blood such as CTCs, exosomes and blood macrophages [12,14] but it has many shortcomings since the DNA content of these structures cannot correlate with the levels of ctDNA detected in blood. Also, the free DNA sequences do not necessarily reflect the same sequences obtained when DNA from CTCs, exosomes, and leukocytes is sequenced. In fact, it shows more dynamic potential compared to them [15,16].
CTCs were first described as a tumor biomarker in 1869 by Ashworth TR [17]. The fact that the only source of CTCs can only be a tumor site, whether it is primary or secondary, making them a reliable biomarker. CTCs contain the whole tumor genome, giving flexibility for analysis and verification of the cell source. They are detected using antibodies that recognize surface markers specific to a tumor and its cellular origin [18], and 5 or more tumor cells in 7ml blood are considered an indication for poor prognosis [15].
Exosomes are a highly specialized category of extracellular vesicles (ECVs) that are formed during the process of autophagy. They are secreted in the extracellular environment when late endosomes fuse with the plasma membrane and not lysosomes for degradation in a complete autophagy scenario [19,20]. These nanovesicles have a distinct and complicated structure that distinguish them from other ECVs [21]. They are membranebound that is derived from the plasma membrane during the formation of an endocytic vesicle of early endosomes. So, identification of their source cells can be achieved by surface markers recognition [22,23]. Though they are not a rich source for cellular DNA, they were found to contain specialized RNA molecule: microRNA (miRNA) [12,24]. miRNAs are believed to have an important in intercellular communications. This role probably affects metastatogenesis [22,25,26], immunological response of the host [27] and even the treatment process [24, 27].
Why Liquid?
The convenience of a liquid biopsy over solid biopsy included clinical, research and practical reasons. The
fact that liquid biopsies are systemic biopsies can be pivotal. This sole criterion overcomes the heterogenicity
of the tumor cellular clones that cannot be avoided with solid biopsy samples. Also, it does not neglect the
distant and inaccessible tumor sites. Based on that a tumor can test positive to a treatment that can test
negative on solid biopsy especially in cases of recurrence or metastases after removal of the primary growth
[28].
Liquid biopsies, in general, have short half-lives, which means that they are more likely to represent a more recent state of the tumor. This makes them an ideal method to track clone selections that can be caused by drugs, or happen with metastases or spontaneously. The concentration/number of the liquid biopsy was found to correlate with the tumor burden in cancer patients [16,29-31]. Thus, it can be a good method to follow up treatment effects[31-33]. This has been extensively studied in many trials. In fact, it was found to have superior results to imaging techniques currently used in practice to evaluate and follow up patients. The effect appears earlier and reflects more sensitivity and specificity since it done through surface markers, in case of exosomes and CTCs, and genetic material, for all of them [10,11,34-38].
Adding to the advantages of a liquid biopsy is its convenience to obtain. Blood, urine and fluid samples can be withdrawn in a timely and cost-effective pattern compared to imaging or re-biopsies if indicated. This also reduces subjecting the patients to increased radiation doses, anesthesia and morbidities that might be associated with them. We have reviewed the causes for the conveniences of liquid biopsy versus tissue biopsy in an article under publication “Circulating Tumor DNA: A review for its role in cancer prevention, diagnosis, and treatment”.
Liquid Biopsy Role as a Biomarker
In 2017, Phallen et al proposed the used ctDNA to diagnose and screen early cancers. The authors have
used a panel of somatic mutations and looked for them randomly in the ctDNA of diagnosed early-stage
cancer patients including colorectal, breast, lung and ovarian. This displayed high concordance with the
corresponding tissue biopsies [39]. Another review article suggested that if these results can be reproduced
in asymptomatic cases the potential for using ct DNA as a screening tool can be very much applicable [40].
However, since ctDNA and CTCs have been researched as biomarkers, their role in the detection of response
to treatment by follow up of the identified tumor mutations was the main aim of many studies[31,41-43].
After all, early prediction of response to treatment and avoiding unnecessary treatment after the development
of resistance is a principal goal for the treating oncologist. Clonal selection by anti-cancer agents and genetic
instability of cancer cells was considered among the reasons for resistance to treatment. Using ctDNA and
CTCs to measure the mutational burden and evolving mutations can be indicative of a patient‘s response to
treatment by therapy [29]. Also, some studies reported that pre-operative levels of ctDNA and CTCs were
found to be highly predictive for the risk of recurrence. Needless to say, patients with higher baseline ctDNA
and CTCs levels were found to have recurrences more frequently than those who had lower levels [36,44].
In our opinion, the most important point in relying on ctDNA and CTCs is their ability to provide an insight to the mutational changes in the tumor cells that resulted from treatment or genetic instability which both imaging and tumor markers are unable to provide. This in itself can be a very strong predictive value in patients who initially found to be responsive to a certain treatment by analyzing the initial tumor tissue biopsied.
If we considered the methods used routinely to monitor patients in oncology clinics, they include imaging and tumor markers. Tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) in colon cancer, and carbohydrate antigen (CA125) in ovarian cancer are used extensively in clinical practice, though the benefit from them is very limited and the specificity is low and recently the United States Preventive Service Task Force (USPSTF) has recommended against their routine use [45].
The other method to evaluate patients’ responses is imaging. Besides the potential hazards from repeated radiation exposure in cancer patients, imaging has proved not to have superior results compared to ctDNA in clinical studies[10,43]. Also, there is risk associated with the technique itself such as contrast dye allergies and ineligibility of really impaired patients. This is without considering the time needed for patient preparation and the resulting in compliance with some patients with treatment.
Challenges of Liquid Biopsy
Despite their many advantages, liquid biopsies did not make their breakthrough in clinical practice. The
reasons for this are multifactorial.
Protocols used by to process the samples of the patients report multiple differences that might affect the
results of the samples, such as pre-analysis processing and storage methods. Since it is a liquid phase sample
and the biomarker have a short half-life, processing time, temperature and time of sample withdrawal has to
be consistent to avoid sample losses. Besides, researchers are required to provide a consistent specification for
the methods used to extract and analyze the samples, starting from sample collection down to sequencing
methods used to interpret the final results. So far, different institutions reproduce their results based on their
own methods without enough inter-institutional evaluations.
When we consider CTCs and exosomes, their primary isolation depends on the identification of surface markers. This increases the frequency of false positives and negatives. Since commercially base isolation kits do not consider tissue dysplasia from epithelial to mesenchymal [46,47]. Though false positives can be excluded by sequencing of their DNA/RNA content, false negative samples will remain unidentified. Some researchers might need to consider a second run for the identification method to identify missed samples on the first run.
Immune identification of exosomes and CTCs is not as cost-efficient when compared to ctDNA regarding the data that can be obtained from one sample of each. However, sequencing for all of them especially with the introduction of second-generation sequencing techniques to improve specificity is an expensive procedure to be carried on in routine practice, but many researchers assume that this cost will drop with the increased utilization of these techniques.
Also, CTCs and exosomes can be more heterogeneous compared to ctDNA. CTCs number for early tumors can be as low as less than 5 cells/7.5ml of blood [15]. This is a narrow margin to differentiate between high and low risk disease.
Exosomes derived from single cell line showed heterogenicity in their sizes, protein content, RNA species and macromolecular composition [48]. This is possibly related to different functional roles that need to be further investigated to decide on the value of their use as a biomarker.
As a result, CTCs and exosomes became more and more a primary target for research, while it plays in favor of ctDNA to be used as a biomarker in routine clinical practice.
Virtosome
Since the genetic material was first isolated from the blood in 1948 [4], researchers have been trying to
identify how and why they are released into the blood. CTCs, exosomes, active secretion, necrosis, apoptosis,
and leukocytes have been included as a source for DNA and RNA in the blood as mentioned before.
However, with the recent advancement in sequencing techniques, ctDNA use in research escalated rapidly. It became increasingly clear that its source can, in fact, be more than one. Identifying the source that can overcome its challenges can speed its use in clinical practice.
One of the sources of ctDNA is active secretion by living cells. This was first described in bacterial cells
[49]. Later, this concept was found to apply to both eukaryotic and prokaryotic cells [50]. Further research
identified this genetic material as a non-membrane bound structure formed of a DNA/RNA lipoprotein
complex [51]. The DNA part is formed in the nucleus and is later assembled with the protein and lipid
components in the cytoplasm [52-54]. Its RNA part is finally added before it is released from the cell
[55]. Its lipoprotein element is believed to play a role in protecting the genetic material from digestion by
nucleases. This complex was identified as virtosome.
A recent report by Cataldi et al. provided a detailed description of the virtosome structure. The researches isolated the DNA/RNA lipoprotein complex from human lymphocytes from both the cytoplasm and from the cell culture medium. They used a multistep centrifugation/ultracentrifugation method to isolate the lipoprotein complex then analyzed its protein, lipid, and nucleic acid contents. Other researchers used agarose gel column chromatography to isolate the complex but reported same similar composition though less specific. According to Cataldi et al., DNA/RNA content represented approximately 40% of the virtosome structure which can be considered as a significant part of its composition. The complex is freshly synthesized and released in the extracellular environment. And its synthesis is regulated by what seems like a negative feedback to prevent the cell from accumulating older complexes [51,52,55,56].
Virtosome is a novel complex, so many of its aspects are still be identified. However, thanks to increased
research for ctDNA and CTCs, researchers became more aware of what to look for when approaching a
liquid biopsy.
Virtosome is capable of entering other cells after its release from the primary cell of origin. It was also
found that the complex was not digested by the lysosomes of the hosting cells. It is then capable of entering
the nucleus of the host cells without noted changes. How this is achieved is not clear yet, however some
researchers think that it might be happening by a process similar to transformation in which DNA plasmid
affect the pH to alter the lysosomal activity [52,55]. Only few research was done to study the effect of
virtosomes on host cells, even though genetic material entry into other tissues and its effects was the scope
many studies [57]. However, many of these studies used DNA from the supernatant of cell culture that
included released virtosomes [58]. Cataldi et al., have reported the effect of virtosomes on lymphocytes. The
authors created two groups of stimulated and unstimulated lymphocytes and extracted the virtosomes from
the cell culture media and the cytosol of both types.
Then they used it to treat the other cell group and recorded its effect on their numbers. While the virtosomes from the unstimulated group produce little effect on the stimulated cells number, the complex extracted from the stimulated cells resulted in about 6.5 times increase in number for the same time of incubation [59]. In another experiment by Anker et al, the complex was extracted from pre-sensitized T-lymphocytes to herpes and polioviruses and used to treat nude mice. The serum of these mice was found positive to antibodies against these viruses depending on which was used to sensitize the T-cells [58].
Free DNA role as a biomarker has been established in many studies [60-62]. The discussed aims were
targeted toward using it for early detection, prognosis, prediction of response, evaluation and follow-up of
patients [10,36,39,63,64]. Virtosomes have the potential to carry the same role since they represent part of
free DNA, thus maintaining the same advantages they offer as a biomarker. They provide more to the quality
of the biomarker since they present the living population of the tumor. This will reduce the fluctuations in the
circulating levels of virtosome that naturally occur in other forms of liquid biopsy following treatment. This
also will make their reliability in reflecting the mutational changes in the survival cell population, thus giving
a more accurate prediction for tumor response to therapy. It also has a good potential to reflect resistant
clones in the tumor. Since it is secreted from living cells regardless of the cell-cycle phase and differentiation,
it can be applied to a wide range of abnormal cellular growths, whether it is aggressive malignancies such
as acute leukemias or chronic and borderline malignancies. A Virtosomal structure is freshly synthesized
and secreted and it takes eighteen hours at most to release all synthesized complexes from the cells. This
time included the time needed by the cell line to uptake the nucleotides from the medium [50]. It is not a
hybrid structure like exosomes, partially made from the cell plasma membrane, and it does not include DNA
formed by unwanted sources such as necrosis.
Several methods for virtosomes isolation were described: Stroun et al. used Cs2SO4/CsCl gradient
centrifugation. The DNA nucleotides were radio-labeled and the density was compared to DNA density
of the producing cells, frog auricles [54]. This technique cannot be applied to extract virtosomes from the
plasma of humans for many reasons. VitosomeDNA is normally not radio-labeled, also, plasma contains
a vast majority of compounds and lipoprotein complexes that probably have the same density. Besides,
the density of the specific virtosome released from a tumor will depend on cell origin which there is no
reference to. The same principle applies to extraction by sucrose gradient centrifugation [65]. Agarose gel or
hydroxyapatite column chromatography were used in few studies conducted in the eighties and nineties of
the last century [52,53]. Considering the advances introduced since that time, it holds a lot of promise since
agarose bead quality, sizes and coating all can produce a highly purified compound.
In our attempt to study released DNA from cells, we used 293Tcells transfected with DsRed containing
plasmid. The cells were incubated in 10% fetal bovine serum DMEM medium. Samples from the media
were collected after 24h, 48h, 72h, up to 6 days. The samples were centrifuged at 17000g to remove debris
and then ran by electrophoresis on 1% agarose gel.
We used three different sets of primers that were designed to detect different portions of the DsRed sequence. We noticed that DsRed was detected at all-time points for all primer sets; however, the detection was inconsistent at 24- and 48-hours samples. This suggested that released DNA are in the form of fragments that might include a certain sequence at one point but not another. This was proved by the consistent detection of DsRed in all the samples beyond 48h when there is sufficient release of DNA to cover all the whole sequence of DsRed. We did not use any DNA isolation methods or kits to extract the DNA from the media.
Since virtosome is a novel complex, research done is very limited. Thus, a lot of questions need to be answered.
For example, it is not clear if the ctDNA research done recently included virtosome as part of their DNA assays. Does the genetic material in the virtosome need to be isolated from their lipoprotein part in order be detected? And are the DNA isolation protocols and commercially available columns capable of isolating virtosome DNA.
DNA in the virtosome was suggested to be a metabolic DNA. It is the DNA synthesized by the cells for non-replication or differentiation purposes and their synthesis occurs even during the resting phases. Some reports have indicated that metabolic DNA is associated with RNA and lipoproteins [66]. So, how close are these reports close to the virtosome description? And do we need to consider these studies as potential effects for virtosomes.
Virtosome contains both RNA and DNA components. Some reports suggested that RNA is messenger RNA (mRNA) since it is formed by a DNA-dependent RNA polymerase. However, others believe that this RNA was capable of altering the biological functions and thus, siRNA is more appropriate [55]. So, characterization of the type and function of RNA in the complex still need to be done.
Bibliography
Hi!
We're here to answer your questions!
Send us a message via Whatsapp, and we'll reply the moment we're available!